EagleBio/IFN分析I型就绪细胞/BM3049

价格
面议
货号:BM3049
浏览量:127
品牌:EagleBio
服务
全国联保
正品保证
正规发票
签订合同
商品描述

iLite Type I IFN Assay Ready Cells

IFN Assay Ready Cells Developed and Manufactured by Svar Life Science

The Eagle Biosciences iLite Type IIFN Assay Ready Cells are intended for:

  • Quantification of interferon alpha or beta activity
  • Determination of Interferon alpha or beta NAbs

Content: iLite® Type I IFN Assay Ready Cells 1 vial (2.5mL)
Alternative Names: Type I Interferon Assay Ready Cells
For Research Use Only


Key benefits of iLite® Assays

  • Highly specific reporter gene cell lines
  • Very sensitive cell line responses (>10 fold inductions)
  • Assay Ready Cells – ready-to-use from the freezer, without culturing of cells
  • Assays within a workday (typically 4-7 hour assays)
  • Normalization gene, which eliminates unwanted matrix effects

Product Overview

In this product, human cells (U937, ATCC# CRL1593.2) engineered to express Firefly Luciferase under the control of an IFN α/β responsive promoter. When IFNα or IFNβ binds to the IFN α/β receptor on the cell surface, the IFN α/β regulated Firefly Luciferase reporter gene construct will be activated, resulting in a luminescent signal.


Principle

Interferon alpha (IFNα) has been widely used to treat chronic viral hepatitis and a wide variety of malignant diseases, including hairy cell leukemia, basal cell carcinoma, chronic myeloid leukemia and cutaneous T-cell lymphoma. Several different recombinant preparations of IFNα are available commercially; the most commonly used formulations include IFNα2a and IFNα2b. A number of studies have shown that development of anti-IFNα neutralizing antibodies (NAbs) is correlated with a loss of IFNα treatment efficacy. Interferon beta (IFNβ) is well established as first line therapy in relapsing/remitting multiple sclerosis. The occurrence of NAbs and binding antibodies (BAbs) to IFNβ has been widely reported. Subjects with NAbs have shown reduced response to treatment with IFNβ, having higher relapse rates, increased MRI activity and higher risk of disease progression. The frequencies and titers of NAbs vary depending on the preparation used, dose and frequency of administration and also the assay used to quantify them.


Products Related to IFN Assay Ready Cells

iLite Insulin Assay Ready Cells
iLite FGF-21 Assay Ready Cells
iLite IL-2 Assay Ready Cells

EagleBio的iLite®分析就绪细胞iLite®  技术基于报告基因检测格式,经过修改和适用于整个药物开发周期中的应用以及生物药物的监测。这些细胞系可以开发用于任何生物制药靶标,并且可以使用相同的细胞系轻松设置药物效力(即药物活性)的测定方法。检验就绪的细胞经过基因工程处理,可与报告基因检验技术一起使用,以检测药物效力和NAb。